Kalbitor Market Report 2026

Kalbitor Market Overview

• The Kalbitor market growth in the historic period has been driven by limited historical treatment options for hae, high morbidity of untreated acute attacks • Market expansion is supported by increasing genetic diagnosis of hae, growth in targeted biologic therapies • Growth Driver: Growing Prevalence Of Hereditary Angioedema Drives Demand For Kalbitor Market Expansion • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kalbitor Market?

Kalbitor (ecallantide) is a recombinant protein and a potent inhibitor of plasma kallikrein, an enzyme involved in the production of bradykinin, a mediator of inflammation and swelling. It is primarily used to treat acute attacks of hereditary angioedema (HAE), a rare genetic disorder characterized by sudden and severe swelling in various body parts. The main indication types of kalbitor are treatment of acute attacks of hereditary angioedema (HAE) and prophylaxis for hereditary angioedema (HAE). Treatment of acute attacks of hereditary angioedema (HAE) involves prompt use of targeted therapies such as C1 inhibitors, kallikrein inhibitors, or bradykinin receptor antagonists to reduce swelling and prevent complications. The formulations are injectable formulations and lyophilized powders for reconstitution, and the patient demographics include pediatric patients, adult patients, and geriatric patients. The distribution channels are direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and it is used by various end users such as hospitals, specialty clinics, home healthcare providers, and emergency departments.

What Is The Kalbitor Market Growth Forecast?

The growth in the forecast period can be attributed to increasing genetic diagnosis of hae, growth in targeted biologic therapies, rising awareness of rare angioedema disorders, expansion of specialty immunology centers, improved reimbursement for orphan drugs. Major trends in the forecast period include rising adoption of kallikrein inhibitors, growth in acute hae attack management, expansion of rare disease emergency therapies, increased focus on rapid symptom control, strengthening specialty care for angioedema.

Global Kalbitor Market Segmentation

1) By Indication: Treatment Of Acute Attacks Of Hereditary Angioedema (HAE), Prophylaxis For Hereditary Angioedema (HAE) 2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution 3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers, Emergency Departments

What Are The Drivers Of The Kalbitor Market?

The increasing prevalence of hereditary angioedema (HAE) is expected to drive the kalbitor market going forward. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body, including the extremities, gastrointestinal tract, and airway. The prevalence of HAE is increasing due to improved awareness, better diagnostic capabilities, and heightened recognition among healthcare providers. Kalbitor (ecallantide), a plasma kallikrein inhibitor, is an essential treatment for managing acute hereditary angioedema (HAE) attacks, improving patient outcomes and quality of life. For instance, in May 2023, according to Frontiers in Allergy, a Switzerland-based peer-reviewed medical journal, a nation-wide epidemiological study in Belgium reported a minimum prevalence of 1.56 per 100,000 population, with 179 patients registered across Belgian reference centers for hereditary angioedema. Therefore, the growing prevalence of hereditary angioedema (HAE) drives the kalbitor industry. The aging population is expected to enhance the kalbitor market going forward. The aging population consists of individuals aged 65 and older, a trend driven by increased life expectancy and declining birth rates. This demographic shift is fueled by advancements in healthcare, medical technology, and enhanced living conditions. Kalbitor is considered for the aging population with hereditary angioedema (HAE), offering a targeted treatment to manage acute swelling attacks while reducing the risks of complications associated with aging. For instance, in January 2024, according to the facts published by the Population Reference Bureau (PRB), a US-based nonprofit research organization, the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase, while their proportion of the total population is anticipated to grow from 17% to 23%. Therefore, the aging population is driving the kalbitor industry. Rising healthcare expenditure is expected to drive the kalbitor market going forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. The rising healthcare expenditure is due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure supports Kalbitor by facilitating broader access to specialized treatments for rare diseases like hereditary angioedema (HAE), ensuring that healthcare systems can allocate resources for innovative therapies, patient management, and the comprehensive care required to address such complex conditions effectively. For instance, in May 2024, according to a report published by Office For National Statistics, a UK-based government agency, total healthcare spending rose by 5.6% in nominal terms from 2022 to 2023, a notable acceleration compared with the 0.9% increase recorded in 2022. Therefore, rising healthcare expenditure drives the kalbitor industry.

Key Players In The Global Kalbitor Market

Major companies operating in the kalbitor market are Takeda Pharmaceutical Company

Regional Insights

North America was the largest region in the kalbitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Kalbitor Market?

The kalbitor market consists of sales of kalbitor (ecallantide) for the treatment of hereditary angioedema (HAE). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kalbitor Market Report 2026?

The kalbitor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kalbitor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.